Prism Biolab Co (TSE:206A) Long-Term Debt: 円0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:206A Prism Biolab Co Ltd TSE:206A
13 GF Score
Price 円157.00
! 2 Warning Signs
View Full Analysis

What is Prism Biolab Co Long-Term Debt?

Prism Biolab Co TSE:206A +1.29% 13 Long-Term Debt is 円0.0 Mil as of Mar. 2026. GuruFocus rates TSE:206A with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Prism Biolab Co's Long-Term Debt for the quarter that ended in Mar. 2026 was 円0.0 Mil.


Prism Biolab Co  (TSE:206A) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Prism Biolab Co Long-Term Debt Related Terms


Prism Biolab Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Prism Biolab Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prism Biolab Co Long-Term Debt Chart

Prism Biolab Co Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Long-Term Debt
0.00 0.00 0.00 0.00

Prism Biolab Co Quarterly Data
Sep22 Sep23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:206A
13GF Score
Prism Biolab Co Ltd TSE:206A
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円0.0 Mil mean?
Prism Biolab Co (TSE:206A) has a Long-Term Debt of 円0.0 Mil as of Mar. 2026.
Is Prism Biolab Co's Long-Term Debt too high?
Prism Biolab Co's current Long-Term Debt is 円0.0 Mil. Overall, Prism Biolab Co has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Prism Biolab Co's Long-Term Debt compare to VRTX and REGN?
Prism Biolab Co's Long-Term Debt of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Prism Biolab Co's current Long-Term Debt is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prism Biolab Co stock overvalued right now?
Prism Biolab Co (TSE:206A) has a current Long-Term Debt of 円0.0 Mil. The current Long-Term Debt is 円0.0 Mil. Prism Biolab Co's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Prism Biolab Co (TSE:206A), the current Long-Term Debt is 円0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prism Biolab Co Business Description

Address 26-1, Muraoka-Higashi 2-chome, Kanagawa Prefecture, Fujisawa, JPN, 251-8555
Prism Biolab Co Ltd is engaged in drug discovery and development based on PepMetics Technology, a proprietary platform technology.
13GF Score

Get the complete analysis for TSE:206A

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円157.00
Price